Collegium Pharmaceutical Inc (COLL)

Cash ratio

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Cash and cash equivalents	US$ in thousands	70,565	38,960	172,894	228,610	238,947	258,532	283,749	269,480	173,688	134,126	122,722	106,698	186,426	193,241	202,771	182,790	174,116	165,423	145,678	116,178
Short-term investments	US$ in thousands	92,198	80,997	98,737	89,438	71,601	46,033	41,721	—	0	—	—	—	—	—	—	—	—	—	—	—
Total current liabilities	US$ in thousands	10,000	459,426	461,717	446,436	457,915	464,612	435,058	412,702	270,114	414,497	415,094	373,573	230,399	268,973	226,843	230,168	191,226	242,437	252,111	244,374
Cash ratio		16.28	0.26	0.59	0.71	0.68	0.66	0.75	0.65	0.64	0.32	0.30	0.29	0.81	0.72	0.89	0.79	0.91	0.68	0.58	0.48

December 31, 2024 calculation

Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($70,565K + $92,198K) ÷ $10,000K
= 16.28

The cash ratio for Collegium Pharmaceutical Inc has shown fluctuations over the quarters, ranging from 0.26 to 16.28. A cash ratio of less than 1 indicates that the company may not have sufficient liquid assets to cover its short-term liabilities. The significant increase in the cash ratio to 16.28 as of December 31, 2024, suggests a substantial improvement in the company's liquidity position, potentially due to a significant increase in cash and cash equivalents. However, caution should be exercised when analyzing such extreme values, as they may be influenced by one-time events or accounting anomalies. Overall, monitoring the trend of the cash ratio over time can provide insights into Collegium Pharmaceutical Inc's ability to meet its short-term obligations using its cash reserves.